Adherence of Stalevo, Entacapone and Levodopa
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00245700 |
Recruitment Status
:
Completed
First Posted
: October 28, 2005
Last Update Posted
: May 23, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
To test if combining two antiparkinson drugs into a single tablet improves accuracy of medicine intake by the patient.
To test if patients with Parkinson's disease who take medicines at regular time intervals have smoother symptom control.
Condition or disease |
---|
Parkinson's Disease |
Study Type : | Observational |
Enrollment : | 14 participants |
Official Title: | Study of Adherence of Stalevo, Entacapone and Levodopa |
Study Start Date : | April 2005 |
Actual Study Completion Date : | July 2006 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 85 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Patients diagnosed with Parkinson's disease aged between 18 and 85 years fulfilling UK Brain Bank criteria.
- Current levodopa therapy prescribed on a regular basis three or more times per day but requiring entacapone because of 'wearing off'
- Able to manipulate electronic monitoring bottles and complete questionnaires
Exclusion Criteria:
- Current use of compliance aid such that study participation would be detrimental to patient's adherence
- Pregnancy or breast feeding
- Excess alcohol (over 21 units per week for women and 28 units for men)
- Mini mental state examination of less than 26.
- Severe depression (Geriatric depression score over 20)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00245700
United Kingdom | |
Southern General Hospital | |
Glasgow, Scotland, United Kingdom, G51 4TF |
Principal Investigator: | Donald G Grosset, MBChB, MD |
Responsible Party: | Dr D Grosset, Southern General Hospital |
ClinicalTrials.gov Identifier: | NCT00245700 History of Changes |
Other Study ID Numbers: |
R050017 Grant from Orion Pharma |
First Posted: | October 28, 2005 Key Record Dates |
Last Update Posted: | May 23, 2008 |
Last Verified: | May 2008 |
Additional relevant MeSH terms:
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases Levodopa |
Entacapone Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Catechol O-Methyltransferase Inhibitors Enzyme Inhibitors |